Home›Earnings›Analyst Ratings›Benzinga spotlights biotech, gold, and oil stock picks…

Benzinga spotlights biotech, gold, and oil stock picks for diversification

The biotech list highlights AbbVie’s Humira as its largest profit contributor and notes the company’s Allergan acquisition.

Reported · Written up by our desk · Analyst Ratings

Benzinga compiled three separate lists aimed at investors looking to diversify, including “Best Biotech Stocks Right Now,” “Best Gold Stocks Right Now,” and “Best Oil Stocks Right Now.” The biotech roundup focuses on companies tied to drug development as the industry continues to evolve following the COVID-19 pandemic, according to the outlet.

In the biotech article, Benzinga spotlights AbbVie, highlighting that Humira accounts for close to half of the company’s current profits. The outlet also notes that AbbVie was spun off from Abbott in early 2013 and that its acquisition of Allergan added drugs in areas including aesthetics and women’s health.

Benzinga also includes Immix Biopharma in its biotech lineup, describing it as a clinical-stage biopharmaceutical company working on tissue-specific therapeutics for oncology and inflammation. The article says the drug candidates are intended to circulate in the bloodstream, exit through tumor blood vessels, and attack components of the tumor microenvironment.

For the gold and oil lists, Benzinga frames gold stocks as generally moving with gold prices and tending to gain value during uncertain times, while its oil roundup discusses the sector’s exposure to disruptions that can impede transport of natural resources, among other pressures.

Latest closeGold $4,431.70 ▲1.9%

More like this

Sources